SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)	3 Months Ended
	Mar. 31, 2025 $ / shares shares
Class of Stock [Line Items]
Number of underlying common stock	40,268,464
Series F Warrants [Member]
Class of Stock [Line Items]
Number of underlying common stock	433,878
Weighted average exercise price | $ / shares	$ 7.4250
Expiration date	June 5, 2025-October 16, 2025
Series G Warrants [Member]
Class of Stock [Line Items]
Number of underlying common stock	1,092,344
Weighted average exercise price | $ / shares	$ 10.230
Expiration date	Feb. 08, 2026
Series I Warrants [Member]
Class of Stock [Line Items]
Number of underlying common stock	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Expiration date	*	[1]
Series J Warrants [Member]
Class of Stock [Line Items]
Number of underlying common stock	12,914,086
Weighted average exercise price | $ / shares	$ 1.3827
Expiration date	*	[1]
Series K Warrants [Member]
Class of Stock [Line Items]
Number of underlying common stock	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Expiration date	*	[1]

[1] The Series I Warrants, Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series I Warrants, 20 trading days following the Company’s announcement of receipt of Premarket Approval from the Food and Drug Administration (“FDA”) for the CGuard Prime Carotid Stent System (135 cm), (B) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 and (C) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begins.